Extracellular matrix-degrading matrix metalloproteinases (MMPs) are invariably upregulated in epithelial cancers and are key agonists in angiogenesis, invasion and metastasis. Yet most MMPs are secreted not by the cancer cells themselves, but by stromal cells within and around the tumor mass. Because the stromal environment can in¯uence tumor formation, and because MMPs can alter this environment, MMPs may also contribute to the initial stages of cancer development. Several recent studies in MMP-overexpressing and MMP-de®cient mice support this possibility, but have required carcinogens or pre-existing oncogenic mutations to initiate tumorigenesis. Here we review the spontaneous development of premalignant and malignant lesions in the mammary glands of transgenic mice that express an autoactivating form of MMP-3/stromelysin-1 under the control of the whey acidic protein gene promoter. These changes were absent in nontransgenic littermates and were quenched by co-expression of a human tissue inhibitor of metalloproteinases-1 (TIMP-1) transgene. Thus by altering the cellular microenvironment, stromelysin-1 can act as a natural tumor promoter and enhance cancer susceptibility.
Introduction
Matrix metalloproteinases (MMPs) are consistently upregulated in epithelial cancers, and considerable evidence indicates that they play an essential role in tumor angiogenesis, invasion and metastasis by virtue of their combined ability to degrade virtually all elements of the extracellular matrix (ECM) (Coussens and Werb, 1996) . Indeed, without the help of ECMdegrading enzymes, cancer cells would probably be unable to cross the matrix barriers that otherwise contain their spread. This straightforward and conceptually appealing supposition forms the basis for current clinical trials of MMP inhibitors as anti-cancer agents. However, in addition to promoting cellular invasion by simply clearing away the surrounding matrix, MMPs can alter cellular signals (Lukashev and Werb, 1998; Werb, 1997) and may therefore in¯uence initial tumor development. If so, then the inhibition of select MMPs during even the earliest stages of cancer progression may oer clinical bene®t.
The MMP stromelysin-1 (MMP-3, Str1) exhibits a number of activities that would make it a particularly good tumor promoter. Like several other MMPs, Str1 was ®rst cloned and later recloned as a cancer-speci®c gene (Matrisian et al., 1985; Muller et al., 1988; Ostrowski et al., 1988) . In addition to degrading numerous ECM components, Str1 can activate gelatinase B and the collagenases, and can activate several serpin-type serine proteinase inhibitors (Sternlicht and Werb, 1999, for review) . Moreover, it can release a number of cell surface molecules, including E-cadherin (Lochter et al., 1997a) , a known contributor to cancer development (Christofori and Semb, 1999; Tlsty, 1998) .
Str1 is expressed by stromal cells during normal mammary gland development, and is strongly upregulated during post-lactational mammary involution when considerable ECM remodeling and alveolar apoptosis occur (Lund et al., 1996; Thomasset et al., 1998; Witty et al., 1995) . Interestingly, E-cadherin cleavage also occurs during involution and may induce apoptosis (Vallorosi et al., 1999) . Alternatively, ECM degradation may induce the apoptosis that occurs during involution. Either way, Str1 could act as an apoptotic stimulus. Indeed, Str1 does induce apoptosis in dierentiated mammary alveolar epithelial cells in culture and in vivo, however it also promotes the proliferation and branching of ductal epithelium Boudreau et al., 1995; Sympson et al., 1994; Thomasset et al., 1998; Witty et al., 1995) . These seemingly contradictory eects can be reconciled by noting that ductal epithelial cells normally divide during branching morphogenesis and persist throughout involution, whereas alveolar epithelial cells do not. Thus the dierentiation status of the target cell may determine its response to Str1. These eects were ®rst observed in transgenic mice with an autoactivating rat Str1 transgene ± (the autoactivating rat Str1 cDNA contained a Val 92 -to-Gly 92 transition within its propeptide domain, thus destabilizing thè cysteine switch' that otherwise maintains enzyme latency (Sanchez-Lopez et al., 1988) ) ± targeted to mammary epithelium by the whey acidic protein (WAP) gene promoter (Sympson et al., 1994) and mouse mammary tumor virus (MMTV) enhancer/ promoter (Witty et al., 1995) . In these mice, Str1 transgene expression resulted in increased ductal branching and precocious lobulo-alveolar development during puberty, basement membrane disruption and unscheduled involution during pregnancy, and alveolar collapse and low milk-protein production during lactation. Expression of the Str1 transgene during pregnancy and lactation also led to enhanced expression of endogenous Str1 by mammary ®broblasts, collagen accumulation (®brosis), neovascularization, and tenascin-C expression (Thomasset et al., 1998) . These changes are not only hallmarks of the reactive stroma seen during involution, but are also seen during cancer progression (Borsi et al., 1992; Rùnnov-Jessen et al., 1996) and may even predispose toward neoplastic epithelial transformation (Jacobs et al., 1999; Jacoby et al., 1997; Kinzler and Vogelstein, 1998; Willenbucher et al., 1999) . Furthermore, the proliferative eects of Str1 could support neoplastic transformation and its apoptotic eects could help select apoptosis-resistant clones. Thus Str1 triggers a number of changes (increased cell proliferation, apoptosis, angiogenesis, and an altered stromal environment) that could potentially promote mammary carcinogenesis.
The above eects, which might be viewed as a prelude to cancer, were observed in transgenic animals under 4 months of age. To further address the potential tumor promoting activity of Str1, mammary gland changes were monitored in WAP-Str1 transgenic mice from 6 ± 24 months of age. We observed the development of spontaneous premalignant lesions and mammary cancers in these mice and the virtual absence of such changes in their nontransgenic littermates and in related bitransgenic mice that co-express a human tissue inhibitor of metalloproteinases (TIMP-1) transgene under the control of the same promoter . These Str1-induced changes which occur in the absence of exogenous mutagens or endogenous oncogene or suppressor gene defects, oer strong evidence that Str1 can indeed act as a natural tumor promoter.
Str1 promotes mammary carcinogenesis
To evaluate the eects of prolonged Str1 expression in the mammary gland, WAP-Str1 transgenic mice from ®ve independent CD-1 founder lines and nontransgenic controls were maintained under similar conditions for up to 2 years . Only 12% of all WAP-Str1 transgenic mice had histologically normal mammary glands. Instead, about three-quarters had moderate-to-severe ®brosis, about half had epithelial hyperplasias, 20% had atypical hyperplasias (dysplasias) or ductal carcinoma in situ, and 7% developed malignant mammary carcinomas (Table 1) . Lymphocytic in®ltrates accompanied these lesions in about half of all transgenic mice. By comparison, 87% of the nontransgenic mice had entirely normal mammary glands, and the remaining 13% had only mild ®brosis, hyperplasia or lymphocytic in®ltration, and none of the more severe lesions seen in the animals expressing the Str1 transgene. These genotype-speci®c dierences were highly signi®cant (P50.002 for carcinoma development and P50.0001 for all other pathologies).
Approximately one-third of the mice from each group were carried through pregnancy and lactation. Parity had no eect on the already low incidence of mammary changes seen in the nontransgenic mice, and slightly increased the incidence of each type of lesion in the transgenic mice (Table 1 ). The hyperplastic and ®brotic lesions also tended to be somewhat more severe in the parous subset of transgenic mice. The absence of more profound dierences between parous and nulliparous mice, despite the use of a pregnancy-responsive promoter, probably re¯ects the low-level activity of the promoter during each estrus cycle which, in turn, would limit the increase in overall lifetime exposure to Str1 that would be gained through parity.
Abnormalities of varying severity were usually seen in all of the mammary glands examined in an individual transgenic mouse, and multiple abnormalities were often seen within individual mammary glands (Figures 1 and 2 ). Fibrotic changes included periductal, intralobular and diuse accumulations of interstitial collagen and ®broblasts (Figure 1 ). In addition, ®brosis was often seen adjacent to or admixed with multiloculated adipocytes (Figure 2 ), a feature that may re¯ect the dedierentiation of adipocytes towards a matrix-producing ®broblastic phenotype. Hyperplastic lesions included discrete hyperplastic alveolar nodules (HANs), multifocal and diuse alveolar hyperplasias, adenomatous hyperplasias, and papillary ductal hyperplasias (Figures 1 ± 4) . Alveolar-type hyperplasias were most common. These were packed with otherwise normal alveoli containing a single layer of luminal epithelial cells surrounded by a single layer of myoepithelial cells (Figure 3 ). Several alveolar hyperplasias displayed evidence of secretory activity with apical lipid vacuolization of the luminal cells, luminal eosinophilic concretions resembling residual (inspissated) milk, and enlarged (ectatic) ducts containing proteinaceous material and lipid droplets (Figures 2  and 3 ). Papillary lesions, on the other hand, contained multilayered mounds of cells within distended ducts (Figure 4 ). In addition, myoepithelial cells were not only present in their normal position between the luminal epithelial cells and basement membrane, but were also abnormally located within the ducts as a result of the inward growth and folding of the papillary projections (Figure 4c ± e). Dysplastic lesions also showed multiple cell layering, but with attenuated myoepithelial cell staining in some areas.
Twelve mammary carcinomas developed in the transgenic mice with only two arising before 1 year of age and an average tumor latency of 18.7 months. Hyperplastic or dysplastic lesions and a ®brotic (scirrhous or desmoplastic) stroma were consistently found adjacent to the malignant tumors (Figures 1 and  5 ). For the most part, however, the tumors were histologically and cytologically diverse. One large adenocarcinoma with adjacent papillary lesions contained unusual, internally located myoepithelial cell islands ( Figure 5 ). Otherwise, myoepithelial cells were uniformly absent in the tumors. The mesenchymal The ®broblast-like sarcomatous cells had malignant cytologic features, composed the majority of some parts of the tumor, and contained similar genomic changes to those seen in the carcinomatous cells , thus indicating that they did not merely represent a stromal response to the malignant epithelial-like cells. Furthermore, both cell populations persisted after serial transplantation to immunocompromised mice. Thus, even though carcinosarcomas are extremely rare in humans and in mice, one-sixth of the tumors in WAP-Str1 mice were of this type, and one-quarter of all tumors exhibited some degree of epithelial-to-mesenchmal phenotypic conversion. This incidence is intriguing in light of recent data indicating that phenotypically normal mammary epithelial cells undergo epithelial-to-mesenchymal conversion in response to Str1 in culture and in vivo (Lochter et al., 1997a; . This phenomenon has been associated with more aggressive malignant behavior (Birchmeier et al., 1996; Gilles and Thompson, 1996) , and careful examination reveals that a large percentage of human tumors, and perhaps all poorly dierentiated tumors, exhibit some degree of epithelial-to-mesenchymal conversion (Oft et al., 1998) . Because most MMPs are stromal (mesenchymal) cell products, cancer cells begin to secrete their own MMPs only when they undergo such an epithelial-to-mesenchymal phenotypic transition (Ahmad et al., 1998; Martorana et al., 1998; Wright et al., 1994) . Thus, Str1 may represent both a cause and a consequence of epithelial-to-mesenchymal conversion. 
TIMP-1 inhibits mammary neoplasia in Str1 transgenic mice
If the proteolytic activity of Str1 is responsible for the development of premalignant and malignant neoplasms in Str1 transgenic mice, then these changes should be quenched by overexpression of its natural inhibitor, TIMP-1. We previously showed that mating the Str1 transgenic mice with mice that overexpress a human TIMP1 transgene driven by the constitutive b-actin gene promoter abolishes the ECM degradation and unscheduled apoptosis otherwise seen in young pregnant Str1 transgenic mice . To test the ability of TIMP-1 to counter the long-term eects of Str1 in the mammary gland, WAP-Str1 transgenic mice were crossed with mice that expressed the human TIMP1 transgene under the control of the same WAP promoter. Using mammary hyperplasia as a surrogate end-point, 73% of 10 ± 16-month-old ospring carrying the Str1 transgene alone, but only Figure 2 Carmine-stained wholemount (a,b) and H&E-stained paran section (c ± e) of an abdominal (#4) mammary gland with diuse hyperplasia (hp), ®brosis (®) and lymphocytic in®ltration (ly) from a 15-month-old parous WAP-Str1 mouse sacri®ced 4 months after its pups were removed. The hyperplastic branches indicated by the arrow in (a) are outlined in (c) and are shown at higher magni®cation in (b and d). These sparse and disproportionately short secondary branches terminate in relatively welldeveloped lobuloalveolar structures and are surrounded by multilocular adipocytes (asterisk). The boxed area to the left of the central lymph node (LN) in c is enlarged in e and shows three hyperplastic areas, each with a distinct histologic appearance. Dilated (ectatic) primary ducts (du) containing considerable amounts of residual secretory material are also evident throughout the gland. Scale bars, 5 mm (a,c), 500 mm (b,d,e) Thus it is the enzymatic activity of Str1 that is required to promote mammary neoplasia.
Other MMPs can promote carcinogenesis
Several recent observations support a role for MMPs early in cancer development. For example, mice that express a human collagenase-1 (MMP-1) transgene in squamous epithelium develop hyperproliferative skin lesions, and although they fail to form tumors spontaneously, they are more sensitive to chemical carcinogens than their non-transgenic littermates (D'Armiento et al., 1995) . Conversely, mice that lack stromelysin-3 (MMP-11) form fewer and smaller DMBA-induced tumors than wild-type mice (Masson et al., 1998) . Moreover, wild-type ®broblasts foster the tumorigenicity of human MCF-7 breast cancer cells in nude mice, whereas ®broblasts without MMP-11 do not (Masson et al., 1998) . Because ECM-associated growth factors are also required for MCF-7 tumorigenicity, the authors propose that MMP-11 may promote tumor formation by causing the release or activation of sequestered growth factors. The lack of matrilysin (MMP-7) in mice carrying the Apc min mutation hinders the development of benign intestinal adenomas (Wilson et al., 1997) , and its overexpression in mammary tissue accelerates mammary tumor formation in mice carrying an MMTV promoter-driven ErbB-2/neu transgene (Rudolph-Owen et al., 1998) . In addition, MMTV-MMP-7 transgenic mice develop premalignant hyperplastic alveolar nodules (HANs) even in the absence of MMTV-neu, whereas their non- . Furthermore, those tumors that develop despite the lack of MMP-9 tend to be more aggressive than usual, suggesting that MMP-9-de®ciency provides pressure for the selection of less dierentiated cancers that are better able to overcome the absence of MMP-9 (unpublished observations). Other MMPs that are highly expressed in malignant disease, such as MMP-19 (Grant et al., 1999) , may also in¯uence cancer progression, but remain essentially unexplored. (Because the GenBank sequences submitted as human MMP-18 and 19 are identical but substantially dierent from the Xenopus MMP-18 sequence, they are designated as MMP-19).
Although the above studies support a role for MMPs in early tumor progression and indicate that MMPs may increase neoplastic risk, they still required pre-existing oncogene or suppressor gene mutations or the administration of chemical carcinogens to achieve tumorigenesis. Here, however, we have described the These changes, which failed to occur in non-transgenic controls, were also quenched by coexpression of a TIMP-1 transgene. Thus their spontaneous development lends even greater support to the likelihood that MMPs profoundly in¯uence early tumor initiation and development. In addition to MMPs, closely related metalloproteinases, such as the membrane-anchored ADAM (a disintegrin and metalloproteinase domain) and the secreted ADAMTS (thrombospondin domain-containing) proteins, are likely to in¯uence cancer progression (Vazquez et al., 1999; Werb and Yan, 1998) . For example, tumor necrosis factor-a converting enzyme (TACE, ADAM-17) can clearly in¯uence cancer progression. Recent data also suggest that an unidenti®ed metalloproteinase causes Fas ligand to be shed from cells, thus enabling them to avoid Fasmediated apoptosis (Mitsiades et al., 1999) . In addition, a unique metalloproteinase that is inhibited by TIMP-1 but not TIMP-2 causes cleavage and shedding of the extracellular domain of the ErbB2/ neu growth factor receptor (Codony-Servat et al., 1999) . Such shedding, which is often observed in breast cancer patients, may have oncogenic consequences and may limit the ecacy of anti-ErbB2-directed therapy. Other ADAM and ADAMTS domains may also in¯uence cancer progression. For example, the cysteine-rich domain of meltrin-a (ADAM-12) can support tumor cell adhesion (Iba et al., 1999) . Some members of these multi-gene families may even play con¯icting roles in cancer due to the presence of domains with distinct biologic activities. For example, the potent anti-angiogenic activity of some ADAMTS (metallospondin) family members (Vazquez et al., 1999) may exert tumor suppressive eects, while other domains may promote tumor progression.
TIMPs may promote and suppress carcinogenesis by distinct mechanisms
If, in fact, MMPs promote carcinogenesis, then their endogenous inhibitors, the TIMPs, should defy cancer development. However, whereas some studies do suggest that TIMPs suppress tumor development, others do not. In support of a tumor suppressive role, antisense depletion of TIMP-1 renders murine 3T3 cells tumorigenic in vivo (Khokha et al., 1989) . In addition, the transformation-promoting activity of the prototypic tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) is inhibited by TIMPs 1 and 2 in culture (Shoji et al., 1997) . Thus, the well-known ability of TPA to promote tumors in vivo may be partly due to its ability to upregulate MMP gene expression (Gack et al., 1994; Reichardt et al., 1998) . On the other hand, TPA also upregulates TIMP-1 gene expression (Logan et al., 1996; Lu et al., 1991) . In double transgenic mice, TIMP-1 overexpression inhibits simian virus 40 T antigen-induced hepatocellular carcinogenesis by inhibiting hepatocyte proliferation and angiogenesis (Martin et al., 1996 (Martin et al., , 1999 . TIMP-1 overexpression also inhibits the tumorigenicity of melanoma and lymphoma cells (Khokha, 1994; KruÈ ger et al., 1997) . However, in an experimental metastasis assay, certain tumor cell lines were better able to grow in the presence of tumor-associated TIMP-1, suggesting that it may protect ECM or cell surface molecules that are critical for cell viability (Soloway et al., 1996) . TIMP-1 overexpression also appears to promote intestinal adenoma formation in Min mice, yet a synthetic MMP inhibitor decreases tumor multiplicity in this same model (Heppner Goss et al., 1998) . This discrepancy may re¯ect the growth-promoting activity of TIMP-1, a function that point-mutation studies indicate is independent of its MMP-inhibitory activity (Chesler et al., 1995) . Indeed, TIMP-1 was initially cloned as`EPA' by virtue of its erythroid-potentiating activity (Docherty et al., 1985) and has been shown to act as a mitogen for other cell types (Bertaux et al., 1991) . Thus it is not entirely counterintuitive that TIMP-1 is often upregulated in human cancers (Kossakowska et al., 1996; Lindsay et al., 1997; Yoshiji et al., 1996) and that such upregulation is predictive for metastatic progression and a poor prognosis (Jung et al., 1997; McCarthy et al., 1999; Mimori et al., 1997; Ree et al., 1997; Zeng et al., 1995) . Although TIMP-1 upregulation may simply be a consequence of the increased matrix remodeling that occurs during invasion, and would certainly hinder the pro-oncogenic and pro-invasive eects of MMPs, emerging evidence indicates that TIMP upregulation could also bene®t tumors. In addition to its growth-stimulatory activity, recent studies indicate that TIMP-1 can upregulate vascular endothelial growth factor expression (Yoshiji et al., 1998) , that it can exert anti-apoptotic activity (Guedez et al., 1998a,b) , and that it may even be internalized by cells and translocated to the nucleus (Ritter et al., 1999) .
Like TIMP-1, TIMP-2 promotes cell growth in culture (Hayakawa et al., 1994; Nemeth et al., 1996; Stetler-Stevenson et al., 1992) and appears to inhibit tumor growth in vivo (Imren et al., 1996) . Although some studies indicate that TIMP-2 expression tends to be similar in tumors and matched normal tissues (Stetler-Stevenson et al., 1990) , others have found a signi®cant correlation between TIMP-2 expression and the development of distant metastases (Ree et al., 1997) . Unlike TIMP-1, TIMP-2 expression is downregulated by TGF-b1 and is unaected by serum and phorbol esters, each of which increase TIMP-1 expression (Leco et al., 1992) .
The role of TIMP-3 in cancer is also unclear. Some studies indicate that TIMP-3 is upregulated in human tumors (UrõÂ a et al., 1994) and may provide an early marker for malignant disease (SP Hawkes, personal communication). Others, however, indicate that the TIMP-3 gene promoter is epigenetically downregulated during cancer development (Bachman et al., 1999) . Like TIMP-1, TIMP-3 is induced during cell transformation in culture (Lu et al., 1991; Staskus et al., 1991) . TIMP-3 is also transiently induced by hepatocyte growth factor (HGF) (Castagnino et al., 1998) , which, in turn, has been implicated in mesenchymal-toepithelial cellular conversion (Tsarfaty et al., 1994) . Interestingly, ectopic overexpression of TIMP-3 can also induce mesenchymal-to-epithelial conversion and loss of malignant characteristics in cultured sarcoma cells, and its antisense depletion has the opposite eect, suggesting that it may be a mediator of HGF activity (Castagnino et al., 1998) . In addition, TIMP-3 is the only known endogenous inhibitor of TACE (Amour et , 1998) . Thus, it may also in¯uence cancer development by inhibiting TACE and other relevant ADAM and ADAMTS family members. Alternatively, some ADAM and ADAMTS proteins may be inhibited by other TIMPs. For example, aggrecanase-1 (ADAMTS-4) is inhibited by TIMP-1 (Tortorella et al., 1999) . Finally, the most recently discovered TIMP, TIMP-4, has been shown to inhibit mammary tumor growth and may be downregulated in human breast cancers (Wang et al., 1997) . Thus it appears that the issue of whether TIMPs defy or exacerbate the eects of cancer-causing agents and mutations is confounded by their multiple and independent functions. Ultimately, the TIMPs may both defy carcinogenicity through their metalloproteinase-inhibitory activity and promote it through their capacity to aect cellular behavior in a metalloproteinase-independent manner.
How MMPs might promote tumor development
Although MMPs are not oncogenic or mutagenic per se, there are several routes whereby they can alter signaling and thus aect the process of neoplastic transformation. By degrading extracellular matrices, MMPs alter cell-matrix interactions and cause the release of bioactive ECM fragments (Lukashev and Werb, 1998) . MMPs can also cleave a growing list of cell surface molecules, including the tumor suppressor E-cadherin . They can release active growth factors, angiogenic factors and angiogenic inhibitors from the cell surface and ECM (Patterson and Sang, 1997; Suzuki et al., 1997) . They can cleave growth factor binding proteins (Fowlkes et al., 1994) and cell surface growth factor receptors (Levi et al., 1996) . They can generate an a1-antitrypsin cleavage product that assists tumor growth and invasion, possibly by modulating NK cell cytotoxicity (Kataoka et al., 1999) . They can foster the recruitment of various host cells by altering the stromal environment (Thomasset et al., 1998; Werb, 1997) , and they may alter cell cycle checkpoint controls and promote genomic instability by aecting cell adhesion (Tlsty, 1998) . MMPs can also induce programmed cell death in anchorage-dependent cells Thomasset et al., 1998) , which could either defy tumor progression or exert pressure for the selection of anchorage-independent and apoptosis-resistant subpopulations, and thus promote progression. Therefore, MMPs may contribute in multiple ways to all stages of cancer progression, including initiation.
The evolution of epithelial cancers is also profoundly reliant on the stromal cells that help make up the tumor mass (Rùnnov-Jessen et al., 1996) . In addition, an altered stromal environment may actually promote neoplastic transformation (Jacobs et al., 1999; Jacoby et al., 1997; Kinzler and Vogelstein, 1998; Willenbucher et al., 1999) . Indeed, stromal changes appeared to presage malignant epithelial changes in the WAP-Str1 transgenic mice (Thomasset et al., 1998) . Thus, because Str1 can alter the extracellular environment and is itself a stromal product, it may be partly responsible for the tumorigenic eects of an altered stroma.
One of the more appealing prospective mechanisms that might be responsible for the tumor promoting capacity of Str1 is that it may alter E-cadherin/bcatenin signaling (Figure 7 ). According to this putative scenario, cleavage of E-cadherin by Str1 or another MMP may increase the cytosolic levels of its intracellular partner, b-catenin. Cytosolic b-catenin, in turn, can be phosphorylated and degraded, or translocated into the nucleus where it then partners with TCF/LEF transcription factors in order to regulate the transcription of genes that contain functional LEF recognition sequences within their promoters (Tlsty, 1998) . In support of this mechanism, Str1-induced epithelial-to-mesenchymal conversion is accompanied by E-cadherin cleavage and a rapid redistribution of b-catenin away from cell-cell contacts towards a more cytoplasmic and perinuclear location (Lochter et al., 1997a) . Furthermore, Str1 induces an early and sustained upregulation of cyclin-D1 (ME Lukashev and Z Werb, unpublished results) . This is consistent with the above mechanism, because cyclin-D1 is regulated by b-catenin (Tetsu and McCormick, 1999) and can exert oncogenic eects in the mammary gland (Wang et al., 1994) . The c-myc proto-oncogene is also regulated by b-catenin/LEF transactivation in colon cancer cells (He et al., 1998) , however signi®cant changes in c-myc expression were not observed by us during Str1-induced phenotypic conversion in mammary epithelial cells (unpublished results). Finally, (Crawford et al., 1999) , and this same pathway may also account for our observation that a number of other MMPs are upregulated during Str1-induced epithelial-to-mesenchymal conversion (Lochter et al., 1997a) .
The ability of MMPs to release growth factors from the cell surface and ECM is also likely to play a critical role in cancer development. Some of these growth factors may in¯uence tumor cells directly, while others may in¯uence neighboring cells, such as endothelial cells, that are required to support tumor growth. Indeed, there is a growing awareness that MMPs promote tumor angiogenesis. In a transgenic model of pancreatic islet cell carcinogenesis, broad-range MMP inhibition suppresses the`angiogenic switch' that occurs during premalignant cancer progression and slows tumor growth during later stages of progression . Gelatinase B is probably an important target of such inhibition, in light of its association with premalignant angiogenesis and its critical role in angiogenesis during bone development (Vu et al., 1998) . On the other hand, some MMPs, such as metalloelastase (MMP-12), matrilysin and gelatinase B, can cleave plasminogen to generate the angiogenesis inhibitor angiostatin (Patterson and Sang, 1997) .
MMPs could also conceivably promote genomic instability by aecting adhesion-dependent cell cycle checkpoint controls (Tlsty, 1998) . Interestingly, statistically nonrandom genomic changes were observed by comparative genomic hybridization in both premalignant and malignant mammary gland lesions in WAPStr1 transgenic mice . The most prevalent change was a deletion in the mid-distal region of mouse chromosome 4 that was present in 70% of the examined WAP-Str1 mammary lesions. This is consistent with the high incidence of chromosome 4 losses seen in two other models of mouse mammary cancer (Donehower et al., 1995; Ritland et al., 1997) . In addition, a more recent study indicates that, in one of these models, the highest incidence of loss of heterozygosity occurs in the same mid-distal region of chromosome 4, thus further implicating this region as a putative tumor suppressor locus (Cool and Jolicoeur, 1999) . Our own data are also consistent with the possibility that Str1 promotes the accumulation of genetic mutations or the selection and clonal expansion of mutant cells.
MMPs clearly do more than just degrade extracellular matrices, and such matrices are not just passive structures. MMPs can in¯uence cell-matrix, cell-cell and paracrine signals that, in turn, control such basic processes as cellular growth, dierentiation, morphogenesis, migration and death. Thus, the importance of MMPs in normal physiologic processes and in pathologic processes other than cancer may also partly stem from their ability to alter cellular signals. Moreover, the role of MMPs in normal physiologic processes and the potential for untoward eects must be considered when designing and undertaking clinical interventions that target the MMPs. A better understanding of the molecular mechanisms responsible for their expanding role in cancer can only bene®t the development of more eective therapeutics and therapeutic stratagies.
